Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
01.08.2025 14:01
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
01.08.2025 14:00
These pharmaceutical giants are well worth a second look.
Stock Market News for Aug 1, 2025
01.08.2025 13:30
Wall Street closed lower on Thursday, pulled down by health care and real estate stocks.
Eli Lilly: The Best Growth Prospects Come At A Price
01.08.2025 12:41
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs suggest caution. Click here to read.
Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
01.08.2025 12:32
Investing.com -- Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with covering weight loss drugs.
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
01.08.2025 11:41
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Novo Nordisk shares hit lowest level in over 3-years
01.08.2025 11:15
Investing.com -- Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
01.08.2025 08:00
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
Eli Lilly: The Worst May Be Already Over (Earnings Preview)
01.08.2025 08:00
Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.
Trump Demands Pharma Companies to Lower US Prices
01.08.2025 07:50
US President Donald Trump sent letters to 17 of the world's largest pharmaceutical companies demanding they charge the US what other countries pay for new medicines. In the letters, sent to Eli Lilly, Novo Nordisk, Pfizer and others, Trump insisted companies immediately lower what they charge Medicaid for existing drugs. Bloomberg Intelligence's Sam Fazeli breaks down the situation.
Trump doubles down on Most Favored Nation plan to target drug prices
01.08.2025 00:33
Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.
Novo Nordisk: Don't Miss Buying This Dip
30.07.2025 14:02
Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO. Learn more on NVO stock here.
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
30.07.2025 12:02
Novo Nordisk is in the sick bay. The stock had its worst day since Black Monday and Wall Street is becoming increasingly skeptical that the weight-loss drugmaker can play catch-up in an increasingly competitive market. Analysts were lowering their expectations on the stock after Novo slashed its full-year outlook Tuesday citing the persistent use of copycat versions of GLP-1s—a type of gut hormone that help regulate blood sugar levels and control appetite—in the U.S., which it vowed to fight.
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
30.07.2025 12:01
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1
MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth
30.07.2025 10:05
MENLO PARK, Calif., July 30, 2025--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
30.07.2025 09:00
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.
IXJ: A Bet On Global Healthcare Recovery
30.07.2025 01:33
IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.
Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
29.07.2025 11:07
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement.
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
29.07.2025 10:45
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The stu
Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital
29.07.2025 05:37
Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the […]